882670-92-0

Basic information

• Product Name: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine
• Synonyms: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine;2-Aminoquinazoline-6-boronic acid pinacol ester;6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-quinazolinamine;(2-AMINOQUINAZOLIN-6-YL)BORONIC ACID PINACOL ESTER
• CAS NO: 882670-92-0
• Molecular Formula: C₁₄H₁₈BN₃O₂
• Molecular Weight: 271.12262
• Mol File: 882670-92-0.mol

Chemical Properties

• Boiling Point: 473.5±37.0 °C(Predicted)
• Appearance: /
• Density: 1.19
• Storage Temp.: 2-8°C(protect from light)
• PKA: 4.97±0.26(Predicted)
• CAS DataBase Reference: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine(882670-92-0)
• EPA Substance Registry System: 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine(882670-92-0)

Safety Data

• Hazardous Substances Data: 882670-92-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine is used as a research compound for exploring its potential pharmacological activities and applications in medicinal chemistry. Its unique structure allows for the investigation of its interactions with biological targets, which could lead to the development of new drugs.
Used in Drug Development:
In the pharmaceutical industry, 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine is utilized as a starting material or intermediate in the synthesis of novel therapeutic agents. Its boron-containing heterocycle may offer advantages in the design and synthesis of drugs with specific mechanisms of action, potentially leading to more effective treatments for various diseases.
Used in Medicinal Chemistry Applications:
6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine serves as a key component in the development of new drugs targeting specific biological pathways. Its incorporation into drug candidates may enhance their selectivity, potency, and efficacy, making it a valuable tool in medicinal chemistry for the creation of innovative therapeutics.

Upstream product

• 190273-89-3 6-bromoquinazolin-2-ylamine 
• 73183-34-3 bis(pinacol)diborane 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 

Downstream Products

• 882670-96-4 3-(2-amino-6-quinazolinyl)-4-methylbenzoic acid 
• 1003312-16-0 6-(2-(4-methoxybenzyloxy)-4-methylpyridin-3-yl)quinazolin-2-amine 

Relevant articles and documents

INHIBITOR OF BRUTON'S TYROSINE KINASE

Disclosed herein is a compound of Formula (I) with a Btk inhibitory activity, wherein all the variables are as defined herein. The compound can be used for the treatment of diseases such as autoimmune diseases, xenogeneic immune diseases, cancers or thromboembolic diseases. Also disclosed is a pharmaceutical composition comprising a compound of Formula (I). Futher provided is a compound capable of inhibiting the activity of Bruton's tyrosine kinase by covalent binding.

GCN2 MODULATOR COMPOUNDS

The disclosures herein relate to novel compounds of Formula (1): or a salt thereof, wherein X, Y, R1, R2, R3, R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with General Control Nondepressible 2 (GCN2).

PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

UREA AND THIOUREA SUBSTITUTED BICYCLES DERIVATIVES AS PESTICIDES

The present invention relates to compounds of formula (I) a compound of formula (1') as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and

Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit

Inhibition of c-Kit has the potential to treat mast cell associated fibrotic diseases. We report the discovery of several aminoquinazoline pyridones that are potent inhibitors of c-Kit with greater than 200-fold selectivity against KDR, p38, Lck, and Src.

Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: Synthesis, SAR, and in vivo anti-inflammatory activity

The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease. Screening of our kinase-preferred collection identified aminoquinazoline 1 as a potent, nonselective inhibitor of Lck and T cell proliferation. In this report, we describe the synthesis and structure-activity relationships of a series of novel aminoquinazolines possessing in vitro mechanism-based potency. Optimized, orally bioavailable compounds 32 and 47 exhibit anti-inflammatory activity (ED50 of 22 and 11 mg/kg, respectively) in the anti-CD3-induced production of interleukin-2 (IL-2) in mice.